Mdrna, Inc.

Metaproteomics, LLC

Mark Fuller

Richard E Herman

Douglas L Badders

Ekaterina G Makienko

John G Babish

Matthew L Tripp

Jeffrey S Bland

Gary K Darland

A natural formulation of compounds isolated or derived from hops which inhibit the activity of cyclooxygenase-2 (COX-2) and/or 5-lipoxygenase (5-LOX) is disclosed. The hops formulations may be administered to a mammal to treat or inhibit a pathological condition associated with the activity of COX-2 and/or 5-LOX in such a mammal.

Inhibition of COX-2 and/or 5-LOX activity by fractions isolated or derived from hops

This disclosure provides the construction, expression, and selection of the mutated genes that encode novel Trp cage polypeptides with desirable binding properties, as well as the novel Trp cage polypeptides themselves. The substances or targets bound by these novel Trp cage polypeptides may be but need not be proteins or polypeptides. Targets may include other biological or synthetic macromolecules as well as other organic and inorganic substances. Further, targets may also include a single or multiple cell or tissue types. The present invention achieves genetic variants of Trp cage-encoding nucleic acids through controlled random mutagenesis of the nucleic acids yielding a mixture of Trp cage polypeptides that are capable of binding targets.

Phage displayed cell binding peptides

The present disclosure relates to the construction, expression, and selection of genes that encode novel Trp cage polypeptides with desirable cell and/or tissue binding properties, as well as the novel Trp cage polypeptides themselves. A polypeptide of this disclosure may contain all or part of amino acid sequence AAADXYXQWLXXXGPXSGRPPPX(SEQ ID NO: 4), wherein Xrepresents an amino acid found in position n, the polypeptide comprising a tryptophan cage (Trp cage).

Growing community of inventors

Seatac, WA, United States of America

Mark Fuller